Sanara MedTech ends advisory deal with Catalyst
Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately on June 2, 2026.
Rhea-AI Filing Summary
Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately on June 2, 2026. The move is tied to a strategic shift toward soft tissue repair and bone fusion products for the surgical market.
The agreement, originally effective March 1, 2023, had engaged Catalyst for transaction and strategic advisory services. Catalyst is affiliated with the Company’s chairman and, with its affiliates, beneficially owns more than 5% of Sanara’s common stock. No fee or penalty was paid for the termination, and covenants on indemnification and confidentiality remain in force.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
Effective date of Services Agreement: March 1, 2023
Services Agreement entry date: March 20, 2023
Termination date: June 2, 2026
+1 more
4 metrics
Effective date of Services Agreement
March 1, 2023
Start of Transaction Advisory Services Agreement with Catalyst
Services Agreement entry date
March 20, 2023
Date Sanara MedTech entered into the Services Agreement
Termination date
June 2, 2026
Effective date of Mutual Termination Agreement with Catalyst
Beneficial ownership threshold
More than 5% of common stock
Catalyst and affiliates’ beneficial ownership of Sanara’s stock
Key Terms
Material Definitive Agreement, Transaction Advisory Services Agreement, Mutual Termination Agreement, indemnification, +1 more
5 terms
Material Definitive Agreement regulatory
"Item 1.02 Termination of a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Transaction Advisory Services Agreement financial
"entered into a Transaction Advisory Services Agreement (the “Services Agreement”) with The Catalyst Group, Inc."
Mutual Termination Agreement regulatory
"the Company entered into a Mutual Termination Agreement (the “Mutual Termination Agreement”) with Catalyst"
indemnification legal
"certain covenants contained in the Services Agreement, including those relating to indemnification and confidentiality"
A contractual promise to cover losses, expenses, or legal claims that arise from specified events, such as breaches of representations or third‑party lawsuits. For investors, indemnification matters because it shifts potential financial risk and future cash outflows from one party to another, similar to a friend agreeing to pay your bill if you’re sued, and can affect deal value, expected returns, and contingent liabilities on the balance sheet.
confidentiality legal
"certain covenants contained in the Services Agreement, including those relating to indemnification and confidentiality"
Confidentiality is the practice of keeping private information—such as business plans, financial data, personnel matters, or trade secrets—restricted to a limited group rather than shared publicly. For investors it matters because breaches can change a company’s competitive edge, trigger legal or regulatory problems, or move markets if sensitive information becomes public; think of it as a lockbox that protects value and reduces unexpected risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What agreement did Sanara MedTech (SMTI) terminate with Catalyst?
Sanara MedTech terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc. This agreement covered transaction advisory, strategic planning, and corporate development services related to potential mergers, acquisitions, financings, and similar transactions for the company.
When did Sanara MedTech’s advisory agreement with Catalyst end?
The advisory agreement between Sanara MedTech and The Catalyst Group ended on June 2, 2026. The parties entered into a Mutual Termination Agreement on that date, making the termination effective immediately under the disclosed terms.
Why did Sanara MedTech (SMTI) end its Services Agreement with Catalyst?
Sanara MedTech ended the Services Agreement with Catalyst in connection with a strategic shift. The company is focusing on soft tissue repair and bone fusion products for the surgical market, reducing its need for the broad transaction advisory services Catalyst provided.
Did Sanara MedTech pay a fee to terminate the Catalyst agreement?
Sanara MedTech did not pay any fee or penalty to terminate the Services Agreement with Catalyst. The Mutual Termination Agreement specifies that the contract ended immediately without a termination payment by the company.
What relationship does Catalyst have with Sanara MedTech’s leadership and stock?
Sanara MedTech’s chairman, Ronald T. Nixon, is the founder and managing partner of Catalyst. Catalyst and its affiliates collectively beneficially own more than 5% of Sanara MedTech’s outstanding common stock, making it a significant related-party counterparty.
Which provisions of the Catalyst Services Agreement remain in effect after termination?
Certain covenants from the Services Agreement, including those relating to indemnification and confidentiality, remain in full force after termination. These continuing obligations follow the original agreement’s terms, even though all other services and commitments have ended.
AI-generated analysis. How Rhea-AI works. Not financial advice.
